Skip to main content
Livermore
Livermore
ZHEN

Abingworth LLP

SEC CIK
0001397144
Latest filing
Feb 10, 2023

The latest 13F from Abingworth LLP covers Q4 2022 (filed Feb 10, 2023): 19 long positions worth $303.5M. The top 10 holdings make up 97.6% of the portfolio, and the largest is Vaxcyte, Inc. (PCVX) at 31.9%. Livermore has 8 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q4 2022

Share counts compared with Q3 2022: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
0
Added
0
Reduced
1
Est. −$103.1M
Sold out
0

Top 5 holdings

Share of this quarter's portfolio value

  1. PCVXVaxcyte, Inc.
    31.9%$96.8MHistory
  2. VRNAVerona Pharma plc
    21.2%$64.2MHistory
  3. VERAVera Therapeutics, Inc.
    18.9%$57.3MHistory
  4. HLVXHilleVax, Inc.
    10.1%$30.8MHistory
  5. ACETAdicet Bio, Inc.
    6.2%$18.9MHistory

Biggest buys

New and added positions, by estimated amount bought

None this quarter.

Largest weight increases

New and added positions, by percentage points of the portfolio gained

None this quarter.

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. PCVXVaxcyte, Inc.
    −$103.1MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. PCVXVaxcyte, Inc.
    −2.31 pp34.2% → 31.9%History

Metrics

13F metrics for Q4 2022, computed only from the numbers in the filings. Definitions below.

Portfolio value
$303.5M
+$11.0M (+3.8%) vs. prior quarter
Positions
19
0 vs. prior quarter
Top 10 concentration
97.6%
Top 10 as share of value
Turnover
0.0%
Q4 2022, one quarter
Average holding period
7.2 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

8 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $440.7M (Q3 2021)

Q1 2021: $289.6MQ2 2021: $323.5MQ3 2021: $440.7MQ4 2021: $412.7MQ1 2022: $352.5MQ2 2022: $312.4MQ3 2022: $292.5MQ4 2022: $303.5M
Q1 2021Q4 2022
13F filings of Abingworth LLP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q4 2022Feb 10, 202319$303.5MPCVXVRNAVERAvs. Q3 2022SEC
Q3 2022Nov 10, 202219$292.5MPCVXVERAHLVXvs. Q2 2022SEC
Q2 2022Aug 15, 202221$312.4MPCVXSRRAVERAvs. Q1 2022SEC
Q1 2022May 16, 202220$352.5MPCVXVERAACETvs. Q4 2021SEC
Q4 2021Feb 16, 202220$412.7MPCVXVERAJSPRvs. Q3 2021SEC
Q3 2021Nov 15, 202120$440.7MPCVXEFTRJSPRvs. Q2 2021SEC
Q2 2021Aug 16, 202119$323.5MPCVXPHATVERAvs. Q1 2021SEC
Q1 2021May 17, 202117$289.6MPCVXPHATSpruce Bio–SEC

13D and 13G filings

Companies where Abingworth LLP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Abingworth LLP does not currently report owning 5% or more of any company.

Latest filings

24 filings on file made by Abingworth LLP or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Abingworth LLP
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
QTTBQ32 Bio Inc.Jul 6, 20267:20 PM ETCarlyle Group Inc.and 9 others13G/A4.10%691.7K shares–Below 5%Jun 30, 2026SEC
JSPRJasper Therapeutics, Inc.Feb 18, 20265:29 PM ETCarlyle Group Inc.and 9 others13D/A3.80%1.09M shares–Below 5%Feb 18, 2026SEC
SPRBSpruce Biosciences, Inc.Feb 18, 20265:27 PM ETCarlyle Group Inc.and 9 others13D/A4.70%50.9K shares–Below 5%Feb 18, 2026SEC
PHATPhathom Pharmaceuticals, Inc.Aug 28, 20254:30 PM ETCarlyle Group Inc.and 10 others13G/A4.90%3.50M shares–Below 5%Aug 28, 2025SEC
NCNANuCana plcApr 18, 20256:04 PM ETCarlyle Group Inc.and 9 others13D/A2.40%3.43M shares–Below 5%Apr 18, 2025SEC
VRNAVerona Pharma plcAug 11, 2022Abingworth LLP13D/AOld format–––SEC
SRRASierra Oncology, Inc.Jul 11, 2022Abingworth LLP13D/AOld format–––SEC
HLVXHilleVax, Inc.May 13, 2022Abingworth LLP13GOld format–New–SEC
SLNOSoleno Therapeutics IncApr 8, 2022Abingworth LLP13D/AOld format–––SEC
VERAVera Therapeutics, Inc.Apr 7, 2022Abingworth LLP13D/AOld format–––SEC
SRRASierra Oncology, Inc.Mar 21, 2022Abingworth LLP13D/AOld format–––SEC
XCURExicure, Inc.Feb 25, 2022Abingworth LLP13D/AOld format–––SEC
PCVXVaxcyte, Inc.Feb 14, 2022Abingworth LLP13G/AOld format–––SEC
SRRASierra Oncology, Inc.Feb 10, 2022Abingworth LLP13D/AOld format–––SEC
SRRASierra Oncology, Inc.Nov 5, 2021Abingworth LLP13D/AOld format–––SEC
JSPRJasper Therapeutics, Inc.Oct 4, 2021Abingworth LLP13DOld format–New–SEC
EFTReFFECTOR Therapeutics, Inc.Sep 3, 2021Abingworth LLP13DOld format–New–SEC
VERAVera Therapeutics, Inc.May 24, 2021Abingworth LLP13DOld format–New–SEC
OKUROnKure Therapeutics, Inc.Apr 20, 2021Abingworth LLP13DOld format–New–SEC
ACETAdicet Bio, Inc.Mar 16, 2021Abingworth LLP13D/AOld format–––SEC